How much weight did participants lose in the retatrutide trial?

Participants in the retatrutide trial lost an average of 28.7% of their body weight on the highest dose after 68 weeks.

What were the main concerns raised by the retatrutide trial results?

Concerns were raised about higher dropout rates due to side effects and the possibility of patients losing too much weight, leading to potential health issues.

How are companies addressing concerns about excessive weight loss from new drugs?

Companies are exploring flexible dosing schedules and focusing on monitoring patient nutrition and hydration to prevent extreme weight loss and ensure overall health.

Home / Health / Lilly's Retatrutide: Too Much of a Good Thing?

Lilly's Retatrutide: Too Much of a Good Thing?

19 Feb

•

Summary

Retatrutide trial participants lost nearly 29% body weight.
Higher dropout rates seen due to side effects.
Concerns rise over extreme weight loss and patient health.

Lilly's Retatrutide: Too Much of a Good Thing?

Eli Lilly's experimental weight-loss drug, retatrutide, has demonstrated remarkable results in a recent trial, with participants achieving an average body weight reduction of 28.7% on the highest dose over 68 weeks. This figure surpasses the approximately 20% weight loss seen with existing medications over similar periods.

Despite these impressive outcomes, the trial noted a higher participant dropout rate, between 12% and 18%, attributed to side effects. Some participants reportedly discontinued the study due to concerns about losing excessive weight, a development that has piqued the interest of outside researchers. Eli Lilly has indicated that retatrutide will target individuals requiring substantial weight loss beyond what current treatments offer.